Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Nature Medicine|August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2015
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell TransplantationSally Arai, Joseph Pidala, Iskra Pusic, et al.
Transplantation and Cellular Therapy|January 18, 2022
Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center ReportAndriyana K Bankova, Joseph Caveney, Bin Yao, et al.
Blood Advances|March 19, 2026
Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANSWilliam Lee Wang, Dasom Lee, Edna Cheung, et al.
Blood Advances|December 13, 2023
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHDCameron S Bader, Anna Pavlova, Robert Lowsky, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPETFederico Simonetta, Israt S Alam, Juliane K Lohmeyer, et al.
Blood Advances|February 11, 2021
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphomaJohn H Baird, David J Epstein, John S Tamaresis, et al.
Blood Advances|January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucelFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Pageof 12